ECONOMIC EVALUATION AND THE POSTPONEMENT OF HEALTH CARE COSTS
| Autor: | Werner B. F. Brouwer, Rudolf T. Hoogenveen, Johan Polder, Talitha L Feenstra, Pieter van Baal |
|---|---|
| Přispěvatelé: | Health Economics (HE), Public Health, Research Group: Economics, Tranzo, Scientific center for care and wellbeing, Science in Healthy Ageing & healthcaRE (SHARE), Clinical Neuropsychology, Methods in Medicines evaluation & Outcomes research (M2O) |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Technology Assessment
Biomedical economic evaluation IMPACT Cost-Benefit Analysis NETHERLANDS Psychological intervention LAST YEAR Life Expectancy Health care FUTURE COSTS MEDICAL COSTS Medicine Humans Operations management GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) health care economics and organizations Actuarial science Cost–benefit analysis business.industry Health Policy Postponement cost effectiveness analysis modeling Cost-effectiveness analysis Health Care Costs PREVENTION Quality-adjusted life year LIFE Economic evaluation Life expectancy ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Smoking Cessation medical costs in life years gained Quality-Adjusted Life Years SMOKING business Models Econometric EXPENDITURE INTERVENTIONS |
| Zdroj: | Health Economics, 20, 432-445. John Wiley & Sons Ltd. Health Economics, 20(4), 432-445. Wiley Health Economics, 20(4), 432-445. Wiley-Blackwell |
| ISSN: | 1057-9230 |
| Popis: | The inclusion of medical costs in life years gained in economic evaluations of health care technologies has long been controversial. Arguments in favour of the inclusion of such costs are gaining support, which shifts the question from whether to how to include these costs. This paper elaborates on the issue how to include cost in life years gained in cost effectiveness analysis given the current practice of economic evaluations in which costs of related diseases are included. We combine insights from the theoretical literature on the inclusion of unrelated medical costs in life years gained with insights from the so-called 'red herring' literature. It is argued that for most interventions it would be incorrect to simply add all medical costs in life years gained to an ICER, even when these are corrected for postponement of the expensive last year of life. This is the case since some of the postponement mechanism is already captured in the unadjusted ICER by modelling the costs of related diseases. Using the example of smoking cessation, we illustrate the differences and similarities between different approaches. The paper concludes with a discussion about the proper way to account for medical costs in life years gained in economic evaluations. Copyright (C) 2010 John Wiley & Sons, Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text